Skip to content

Endophenotype for Alcohol Misuse in Healthy Minority Populations

Defining an Endophenotype for Alcohol Misuse: A Focus On Minority Populations

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00256451
Acronym
DEFINE
Enrollment
43
Registered
2005-11-21
Start date
2005-11-30
Completion date
2008-05-31
Last updated
2019-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Naltrexone, Alcohol

Brief summary

The purpose of the study is to understand the relationship between what an individual inherited from their family (genetics), how they respond and feel after drinking alcohol, and how they respond to pre-treatment with naltrexone, a medication that blocks some of the effects of alcohol and is approved for the treatment of alcoholism. The investigators are conducting this study on those of African descent because there is almost no research focused on this group and the association with genetics. The investigators seek to enroll 40 people in the study. Participation will consist of 4 different alcohol challenge sessions in a cross over design. Each session will be separated by at least 10 days. In total, there will be four challenge sessions.

Detailed description

We propose to test the degree to which specific genetic markers alter the relationship between subjective and objective measures of response to alcohol ingestion among non-alcohol dependent adults of African descent in a laboratory environment. To meet this aim, non-alcohol dependent adults of African descent will be recruited for participation to meet the N-goal of 40 trial completers. After consenting, genotyping, and completing the baseline assessment, they will participate in four separate alcohol challenge sessions separated by at least 10 days. During each of the sessions, subjects will be administered alcohol or sham drinking challenge sessions and pretreatment with either naltrexone (50 mg/day) or placebo in a double-blind fashion. The order of the four sessions will be randomly assigned. During each session, physiological and subjective response will be measured. We will select subjects to assure equal number of participants with at least one copy of the Val6 allele compared to those homozygous for the Ala6 allele.

Interventions

DRUGNaltrexone

50 mg/day for two days prior to the alcohol challenge session

DRUGplacebo

placebo pills

OTHERalcohol

190 proof alcohol prepared to 11% volume mixed with fruit juice.

OTHERSham alcohol

non-alcoholic placebo alcohol

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male or female and 21 years of age or older * Drinks less than an average of 21 drinks/week with no more than 2 binge episodes per week * Of African descent by self report

Exclusion criteria

* Meets DSM-IV criteria for lifetime dependence on any substance other than nicotine * Subjects who test positive on the urine drug screen for opioids, cocaine, marijuana, or amphetamine at the screening visit * Subjects who meet current or lifetime DSM-IV criteria for bipolar affective disorder, schizophrenia, or any psychotic disorder * The presence of unstable or serious medical illness; including history of stroke, seizure disorder, severe liver disease (AST or ALT \> 5X normal at the time of randomization), or unstable cardiac disease * Needs treatment with any psychotropic medication (antidepressant, antipsychotic, benzodiazepine, or mood stabilizing medication) * Pre-menopausal female subjects who are pregnant, nursing, or not using a reliable method of contraception * Insulin-dependent diabetes * Any medical or psychological condition that could jeopardize the subject's safe participation in the trial as determined by the PI.

Design outcomes

Primary

MeasureTime frameDescription
Biphasic Alcohol Effects Scale - StimulationDuring challenge sessionsChange from baseline to peak for the feeling of stimulation after alcohol ingestion Biphasic Alcohol Effects Scale - Stimulation: sum of 7 items each rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, higher scores=worse outcome.
Profile of Mood States - Vigorduring the challenge sessionChange from baseline to peak for the amount of Vigor experienced after alcohol ingestion Profile of Mood States - Vigor: sum of 6 items each rated on 5 point Likert scale (0: not at all, 4: extremely). Minimum=0, maximum=20, higher scores = better outcome
Subjective High From Alcohol Scaleduring the alcohol ingestionChange from baseline to peak for the self reported feeling of being high after drinking Subjective High from Alcohol Scale: sum of 15 items rated on a 8 point Likert scale (0-7). Minimum=0, maximum=105, higher scores=worse outcomes

Secondary

MeasureTime frameDescription
Biphasic Alcohol Effects Scale - SedationDuring the challenge sessionChange from baseline to peak of the amount of sedation post ingestion of alcohol Biphasic alcohol effects scale - Sedation: sum of 7 items rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, lower scores=worse outcomes
Profile of Mood States - Fatigue ScaleDuring the challenge sessionChange from baseline to peak of the degree of fatigue experienced after alcohol ingestion Profile of Mood States - Fatigue scale: sum of 5 items rated on 5-point Likert scale (0=not at all, 4=extremely). Minimum=0, maximum=20, higher score=worse outcome

Countries

United States

Participant flow

Pre-assignment details

Participants were only randomized to 4 sequences and not to all 12 possible sequences.

Participants by arm

ArmCount
Overall Study Population
all participants in the cross over study
43
Total43

Baseline characteristics

CharacteristicOverall Study Population
Age, Continuous35.5 years
STANDARD_DEVIATION 12.9
Alcohol use3.2 total number of drinks in the week prior
STANDARD_DEVIATION 4.9
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
43 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Sex: Female, Male
Female
23 Participants
Sex: Female, Male
Male
20 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 400 / 380 / 390 / 38
other
Total, other adverse events
0 / 400 / 380 / 390 / 38
serious
Total, serious adverse events
0 / 400 / 380 / 390 / 38

Outcome results

Primary

Biphasic Alcohol Effects Scale - Stimulation

Change from baseline to peak for the feeling of stimulation after alcohol ingestion Biphasic Alcohol Effects Scale - Stimulation: sum of 7 items each rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, higher scores=worse outcome.

Time frame: During challenge sessions

ArmMeasureValue (MEAN)Dispersion
ALC and NALBiphasic Alcohol Effects Scale - Stimulation11.3 units on a scaleStandard Deviation 10.1
Placebo ALC and NALBiphasic Alcohol Effects Scale - Stimulation3.9 units on a scaleStandard Deviation 5.1
Placebo Pill and ALCBiphasic Alcohol Effects Scale - Stimulation8.7 units on a scaleStandard Deviation 7.6
Placebo Pill and Placebo ALCBiphasic Alcohol Effects Scale - Stimulation3.2 units on a scaleStandard Deviation 4.6
Primary

Profile of Mood States - Vigor

Change from baseline to peak for the amount of Vigor experienced after alcohol ingestion Profile of Mood States - Vigor: sum of 6 items each rated on 5 point Likert scale (0: not at all, 4: extremely). Minimum=0, maximum=20, higher scores = better outcome

Time frame: during the challenge session

ArmMeasureValue (MEAN)Dispersion
ALC and NALProfile of Mood States - Vigor2.1 units on a scaleStandard Deviation 2.5
Placebo ALC and NALProfile of Mood States - Vigor1.1 units on a scaleStandard Deviation 1.2
Placebo Pill and ALCProfile of Mood States - Vigor1.8 units on a scaleStandard Deviation 1.4
Placebo Pill and Placebo ALCProfile of Mood States - Vigor1.2 units on a scaleStandard Deviation 1.3
Primary

Subjective High From Alcohol Scale

Change from baseline to peak for the self reported feeling of being high after drinking Subjective High from Alcohol Scale: sum of 15 items rated on a 8 point Likert scale (0-7). Minimum=0, maximum=105, higher scores=worse outcomes

Time frame: during the alcohol ingestion

ArmMeasureValue (MEAN)Dispersion
ALC and NALSubjective High From Alcohol Scale17.9 units on a scaleStandard Deviation 17.2
Placebo ALC and NALSubjective High From Alcohol Scale4.5 units on a scaleStandard Deviation 5.4
Placebo Pill and ALCSubjective High From Alcohol Scale14.7 units on a scaleStandard Deviation 13.1
Placebo Pill and Placebo ALCSubjective High From Alcohol Scale2.7 units on a scaleStandard Deviation 5.3
Secondary

Biphasic Alcohol Effects Scale - Sedation

Change from baseline to peak of the amount of sedation post ingestion of alcohol Biphasic alcohol effects scale - Sedation: sum of 7 items rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, lower scores=worse outcomes

Time frame: During the challenge session

ArmMeasureValue (MEAN)Dispersion
ALC and NALBiphasic Alcohol Effects Scale - Sedation14.8 units on a scaleStandard Deviation 13.7
Placebo ALC and NALBiphasic Alcohol Effects Scale - Sedation13.4 units on a scaleStandard Deviation 16.1
Placebo Pill and ALCBiphasic Alcohol Effects Scale - Sedation15.9 units on a scaleStandard Deviation 15.8
Placebo Pill and Placebo ALCBiphasic Alcohol Effects Scale - Sedation15.4 units on a scaleStandard Deviation 16.3
Secondary

Profile of Mood States - Fatigue Scale

Change from baseline to peak of the degree of fatigue experienced after alcohol ingestion Profile of Mood States - Fatigue scale: sum of 5 items rated on 5-point Likert scale (0=not at all, 4=extremely). Minimum=0, maximum=20, higher score=worse outcome

Time frame: During the challenge session

ArmMeasureValue (MEAN)Dispersion
ALC and NALProfile of Mood States - Fatigue Scale2.2 units on a scaleStandard Deviation 2.1
Placebo ALC and NALProfile of Mood States - Fatigue Scale1.6 units on a scaleStandard Deviation 1.4
Placebo Pill and ALCProfile of Mood States - Fatigue Scale2.0 units on a scaleStandard Deviation 1.6
Placebo Pill and Placebo ALCProfile of Mood States - Fatigue Scale1.5 units on a scaleStandard Deviation 1.4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026